MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ijrobp.2023.10.017

Медицинская библиотека · International journal of radiation oncology, biology, physics · 2023

SABR for Sarcoma Lung Metastases: Indications for Treatment and Guidance for Patient Selection.

Farooqi Ahsan S, Yoder Alison K, Lin Heather Y, Pasalic Dario, Erasmus Jeremy, Betancourt Sonia, Wernz Cort, Mitra Devarati, Zarzour Maria A, Somaiah Neeta, Conley Anthony, Ratan Ravin, Livingston Andrew, Araujo Dejka M, Roland Christina, Scally Christopher, Keung Emily, Gandhi Saumil N, Ashleigh Guadagnolo B, Nguyen Quynh-Nhu, Bishop Andrew J

СтатьяПеревод пока не подготовлен

Аннотация

PURPOSE: The lungs are the most common site of metastasis for patients with soft tissue sarcoma. SABR is commonly employed to treat lung metastases among select patients with sarcoma with limited disease burden. We sought to evaluate outcomes and patterns of failure among patients with sarcoma treated with SABR for their lung metastases.

METHODS AND MATERIALS: We performed a retrospective review of patients treated at a tertiary cancer center between 2006 and 2020. Patient disease status at the time of SABR was categorized as either oligorecurrent or oligoprogressive. The Kaplan-Meier method was used to estimate disease outcomes. Uni- and multivariable analyses were conducted using the Cox proportional hazards model.

RESULTS

We identified 70 patients with soft tissue sarcoma treated with SABR to 98 metastatic lung lesions. Local recurrence-free survival after SABR treatment was 83% at 2 years. On univariable analysis, receipt of comprehensive SABR to all sites of pulmonary metastatic disease at the time of treatment was associated with improved progression-free survival (PFS; hazard ratio [HR], 0.51 [0.29-0.88]; P = .02). On multivariable analysis, only having systemic disease controlled at the time of SABR predicted improved PFS (median PFS, 14 vs 4 months; HR, 0.37 [0.20-0.69]; P = .002) and overall survival (median overall survival, 51 vs 14 months; HR, 0.17 [0.08-0.35]; P < .0001).

CONCLUSIONS

SABR provides durable long-term local control for sarcoma lung metastases. The most important predictor for improved outcomes was systemic disease control. Careful consideration of these factors should help guide decisions in a multidisciplinary setting to appropriately select the optimal candidates for SABR.

Для цитирования: Farooqi Ahsan S, Yoder Alison K, Lin Heather Y, Pasalic Dario, Erasmus Jeremy, Betancourt Sonia, Wernz Cort, Mitra Devarati, Zarzour Maria A, Somaiah Neeta, Conley Anthony, Ratan Ravin, Livingston Andrew, Araujo Dejka M, Roland Christina, Scally Christopher, Keung Emily, Gandhi Saumil N, Ashleigh Guadagnolo B, Nguyen Quynh-Nhu, Bishop Andrew J. SABR for Sarcoma Lung Metastases: Indications for Treatment and Guidance for Patient Selection.. International journal of radiation oncology, biology, physics. 2023. DOI: 10.1016/j.ijrobp.2023.10.017.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.